Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans

Atherosclerosis

Volumn 235, Issue 1, 2014, Pages 223-229

  Enkhmaa, Byambaa ^a   Anuurad, Erdembileg ^a   Zhang, Wei ^a   Berglund, Lars ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apo(a) sizes; Corrections for the contribution of Lp(a); Ethnicity; K4 repeats; Plasma lipids

Indexed keywords

APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL; ISOPROTEIN;

ADULT; AFRICAN AMERICAN; AGE; ALLELE; ARTICLE; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; FEMALE; GENDER; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; ATHEROSCLEROSIS; BLOOD; ETHNOLOGY; GENETICS; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR;

AFRICAN AMERICANS; AGED; ALLELES; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, LDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PROTEIN ISOFORMS; RISK ASSESSMENT; RISK FACTORS;

EID: 84901830254     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.04.035     Document Type: Article

References (50)

1. Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., White I.R., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
2. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301:2331-2339.
3. Clarke R., Peden J.F., Hopewell J.C., Kyriakou T., Goel A., Heath S.C., et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009, 361:2518-2528.
4. Nordestgaard B.G., Chapman M.J., Ray K., Boren J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010, 31:2844-2853.
5. McLean J.W., Tomlinson J.E., Kuang W.J., Eaton D.L., Chen E.Y., Fless G.M., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
6. Koschinsky M.L., Beisiegel U., Henne-Bruns D., Eaton D.L., Lawn R.M. Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. Biochem 1990, 29:640-644.
7. Lackner C., Cohen J.C., Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993, 2:933-940.
8. van der Hoek Y.Y., Wittekoek M.E., Beisiegel U., Kastelein J.J., Koschinsky M.L. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet 1993, 2:361-366.
9. Boerwinkle E., Leffert C.C., Lin J., Lackner C., Chiesa G., Hobbs H.H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992, 90:52-60.
10. Marcovina S.M., Albers J.J., Jacobs D.R., Perkins L.L., Lewis C.E., Howard B.V., et al. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study. Arterioscler Thromb 1993, 13:1037-1045.
11. Parra H.J., Luyeye I., Bouramoue C., Demarquilly C., Fruchart J.C. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta 1987, 168:27-31.
12. Paultre F., Pearson T.A., Weil H.F., Tuck C.H., Myerson M., Rubin J., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000, 20:2619-2624.
13. Wood R.J., Volek J.S., Davis S.R., Dell'Ova C., Fernandez M.L. Effects of a carbohydraterestricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab (Lond) 2006, 3:19.
14. Sofi F., Fatini C., Sticchi E., Lenti M., Gori A.M., Giusti B., et al. Fish intake and LPA 93C>T polymorphism: gene-environment interaction in modulating lipoprotein (a) concentrations. Atherosclerosis 2007, 195:e147-e154.
15. Catena C., Novello M., Dotto L., De Marchi S., Sechi L.A. Serum lipoprotein(a) concentrations and alcohol consumption in hypertension: possible relevance for cardiovascular damage. J Hypertens 2003, 21:281-288.
16. Guyton J.R., Dahlen G.H., Patsch W., Kautz J.A., Gotto A.M. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis 1985, 5:265-272.
17. Corsetti J.P., Sterry J.A., Sparks J.D., Sparks C.E., Weintraub M. Effect of weight loss on serum lipoprotein(a) concentrations in an obese population. Clin Chem 1991, 37:1191-1195.
18. Lobo R.A., Notelovitz M., Bernstein L., Khan F.Y., Ross R.K., Paul W.L. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol 1992, 166:1182-1188. discussion 88-90.
19. Carlson L.A., Hamsten A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989, 226:271-276.
20. Shewmon D.A., Stock J.L., Rosen C.J., Heiniluoma K.M., Hogue M.M., Morrison A., et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994, 14:1586-1593.
21. Anuurad E., Rubin J., Chiem A., Tracy R.P., Pearson T.A., Berglund L. High Levels of Inflammatory Biomarkers Are Associated with Increased Allele-Specific Apolipoprotein(a) Levels in African-Americans. J Clin Endocrinol Metab 2008, 93:1482-1488.
22. Enkhmaa B., Anuurad E., Zhang W., Pearson T.A., Berglund L. Association of Lp-PLA(2) activity with allele-specific Lp(a) levels in a bi-ethnic population. Atherosclerosis 2010, 211:526-530.
23. Enkhmaa B., Anuurad E., Ozturk Z., Zhang W., Pearson T.A., Berglund L. Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Transl Res 2011, 158:92-98.
24. Enkhmaa B., Anuurad E., Zhang W., Abbuthalha A., Li X.D., Dotterweich W., et al. HIV Disease Activity as a Modulator of Lipoprotein(a) and Allele-Specific Apolipoprotein(a) Levels. Arterioscler Thromb Vasc Biol 2013, 33:387-392.
25. Jenner J.L., Ordovas J.M., Lamon-Fava S., Schaefer M.M., Wilson P.W., Castelli W.P., et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation 1993, 87:1135-1141.
26. Slunga L., Asplund K., Johnson O., Dahlen G.H. Lipoprotein (a) in a randomly selected 25-64 year old population: the Northern Sweden Monica Study. J Clin Epidemiol 1993, 46:617-624.
27. Bovet P., Rickenbach M., Wietlisbach V., Riesen W., Shamlaye C., Darioli R., et al. Comparison of serum lipoprotein(a) distribution and its correlates among black and white populations. Int J Epidemiol 1994, 23:20-27.
28. Contois J.H., Lammi-Keefe C.J., Vogel S., McNamara J.R., Wilson P.W., Massov T., et al. Plasma lipoprotein(a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay. Clin Chim Acta 1996, 253:21-35.
29. Hernandez C., Chacon P., Garcia-Pascual L., Simo R. Differential influence of LDL cholesterol and triglycerides on lipoprotein(a) concentrations in diabetic patients. Diabetes Care 2001, 24:350-355.
30. Moon J.Y., Kwon H.M., Kwon S.W., Yoon S.J., Kim J.S., Lee S.J., et al. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology 2007, 108:282-289.
31. Pedreno J., Fernandez R., Ballester A., Jornet A., Uson M., Canela J., et al. Lack of association of serum lipoprotein (a) levels with type-2 diabetes mellitus in patients with angiographically defined coronary artery disease. Int J Cardiol 2000, 74:159-167.
32. Gaw A., Docherty G., Brown E.A., Ford I. Predictors of plasma lipoprotein(a) concentration in the West of Scotland Coronary Prevention Study cohort. Atherosclerosis 1999, 143:445-450.
33. Zlatohlavek L., Zidkova K., Vrablik M., Haas T., Prusikova M., Svobodova H., et al. Lipoprotein(a) and its position among other risk factors of atherosclerosis. Physiol Res 2008, 57:777-783.
34. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008, 117:176-184.
35. Seman L.J., Breckenridge W.C. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochemistry and cell biology = Biochimie et biologie cellulaire 1986, 64:999-1009.
36. Anuurad E., Rubin J., Lu G., Pearson T.A., Holleran S., Ramakrishnan R., et al. Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res 2006, 47:2475-2481.
37. Rubin J., Paultre F., Tuck C.H., Holleran S., Reed R.G., Pearson T.A., et al. Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res 2002, 43:234-244.
38. McGowan M.W., Artiss J.D., Strandbergh D.R., Zak B. A peroxidase-coupled method for the colorimetric determination of serum triglycerides. Clin Chem 1983, 29:538-542.
39. Allain C.C., Poon L.S., Chan C.S., Richmond W., Fu P.C. Enzymatic determination of total serum cholesterol. Clin Chem 1974, 20:470-475.
40. Warnick G.R., Benderson J., Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
41. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
42. Maciejko J.J., Levinson S.S., Markyvech L., Smith M.P., Blevins R.D. New assay of apolipoproteins A-I and B by rate nephelometry evaluated. Clin Chem 1987, 33:2065-2069.
43. Kovar J., Havel R.J. Sources and properties of triglyceride-rich lipoproteins containing apoB-48 and apoB-100 in postprandial blood plasma of patients with primary combined hyperlipidemia. J Lipid Res 2002, 43:1026-1034.
44. Kimak E., Solski J. ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail 2002, 24:485-492.
45. Jenner J.L., Seman L.J., Millar J.S., Lamon-Fava S., Welty F.K., Dolnikowski G.G., et al. The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings. Metabolism 2005, 54:361-369.
46. Demant T., Seeberg K., Bedynek A., Seidel D. The metabolism of lipoprotein(a) and other apolipoprotein B-containing lipoproteins: a kinetic study in humans. Atherosclerosis 2001, 157:325-339.
47. Frischmann M.E., Ikewaki K., Trenkwalder E., Lamina C., Dieplinger B., Soufi M., et al. In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a). Atherosclerosis 2012, 225:322-327.
48. Frischmann M.E., Kronenberg F., Trenkwalder E., Schaefer J.R., Schweer H., Dieplinger B., et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007, 71:1036-1043.
49. Bachorik P.S., Lovejoy K.L., Carroll M.D., Johnson C.L., Albers J.J., Marcovina S.M. Measurement of apolipoproteins A-I and B during the National Health and Nutrition Examination Survey (NHANES) III. Clin Chem 1994, 40:1915-1920.
50. Ford E.S., Li C., Sniderman A. Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988-1991 to 2005-2008. Cardiovasc Diabetol 2013, 12:26.